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Abstract
The opioid epidemic has led to a chain reaction of public health concerns, including an increase
in heroin usage, injection drug abuse, incidence of hepatitis C virus (HCV), and HIV
transmission. There have been few population-based studies investigating the clinical and sociodemographic data associated with opioid use in Nevada (Feng et al., 2016; Frank, 2000) and few
studies investigating the intravenous drug user (IDU) population in Clark County. On February
2017, Clark County’s first syringe exchange program (SEP) opened its doors to the IDU
population. This study provides an updated analysis of opioid-related injuries within Nevada and
provides a first-time analysis of the IDU population within Clark County. According to the 2017
Center of Health Information Analysis (CHIA), there were 9,064 opioid-related injuries in the
state of Nevada. The most common comorbidities associated with opioid-related injuries were
chronic bodily pains (50.2%), malnutrition (47.3%), nicotine dependence (44.7%), affective
disorders (32.4%), and hypertension (28.8%). There was a higher proportion of 18-35 year olds
who used SEPs as compared to 18-35 year olds who used hospitals. One Clark County zip code
had both high frequencies for opioid-related hospitalizations and injection drug use. In order to
implement interventions and programs to battle the opioid epidemic and the consequent public
health effects, we must first understand the associations between opioid-related hospitalizations
and the IDU population.
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Introduction
The U.S. Secretary of the Department of Health and Human Services (HHS) declared the
current opioid epidemic a public health emergency (Department of Health and Human Services
[HHS], 2017a). In 2016, more than 11 million people abused prescription opioids (synthetic pain
relievers) (CDC, 2018b) and approximately 116 people die each day from an opioid-related drug
overdose (HHS, 2017b). Prescription opioids such as oxycodone, hydrocodone, and methadone
reportedly caused four times more deaths in 2016 compared to 1999 (CDC, 2018c); this does not
reflect the use of illicit opioids like heroin. These increases in opioid abuse and death are related
to several public health concerns derived from the opioid epidemic.
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Background and Significance
Public Health Concern – Increase of Heroin Usage
The opioid epidemic has led to a chain reaction of public health concerns, costing the
U.S. 56 million dollars in annual societal costs (Rossiter et al., 2014). One of the concerns has
been the increased number of new heroin users (CDC, 2018a). Among new heroin users, 75%
reported the use of prescription opioids before trying heroin (CDC, 2018a). It is common for
prescription opioid users to advance to heroin use (Cicero et al., 2014; Lankenau et al., 2012;
Mars et al., 2014; Peavy et al., 2012) because of its accessibility, affordability, pain relieving,
and euphoric affects (Cicero et al., 2012; Cicero et al., 2014; Lankenau et al., 2012; Library of
Congress, 2014; Mars et al., 2014). In 2016, HHS reported 170,000 people used heroin for the
first time and 948,000 people were currently using heroin. In addition, there were 15,469 deaths
attributed to overdosing on heroin alone (HHS, 2017b).
Public Health Concern – Increase of Injection Drug Abuse
The number of IDUs have increased consequential to the abuse of opioids and heroin.
IDUs report that injection of heroin is easier as opposed to the complex break down and
extraction of prescription opioids (Cicero et al., 2014). Injection of drugs, as opposed to
ingestion or inhalation, is the most dangerous route of drug administration. It may lead to
injection-related endocarditis, increased risk for overdose, emergency department visits,
mortality, and infectious disease transmission (Black et al., 2013; Havens et al., 2007).
According to Jones, Christensen and Gladden (2017) injection drug abuse increased from 11.7%
to 18.1% between 2004 and 2013. As injection drug abuse increases, we can expect the number
of IDUs who do not inject safely (i.e. the reusing and sharing of syringes and injection
equipment) to increase simultaneously (CDC, 2018d; Strenski, 2000).
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Public Health Concern – Increase of HIV/ HCV Transmission
There are many injuries associated with injection drug use; however, the transmission of
blood-borne viruses, such as HIV and HCV, can have catastrophic results. From 2011 to 2015,
new HCV infections had doubled and approximately 6% of new HIV diagnoses were attributed
to injection drug use (CDC, 2018d). According to the CDC (1998), injection drug use was the
second leading cause of HIV infection (Marx et al., 2001) and continues to be one of the top
methods of HIV transmission within the U.S. (CDC, 2018d). This is attributed to the reuse and
sharing of injection equipment (Strenski, 2000). Sterile syringes are meant to be used one time
and then disposed of; however, obtaining sterile syringes and injection equipment may be
difficult for IDUs (Aldrich, 1993).
Syringe Exchange Programs and Public Health Benefits
One of the proposed solutions to address these public health concerns are SEPs. SEPs
offer sterile injection equipment and social services without judgement and free of charge.
During the wake of the HIV pandemic in the 1980’s, distributing sterile syringes to IDUs was
controversial because a prescription was required (Aldrich, 1993). Anyone caught distributing
sterile syringes including public health professionals were arrested because authorities believed
they were enabling the use of illicit drugs (Aldrich, 1993). Today, IDUs may attempt to purchase
sterile syringes, but may be denied their purchase due to their appearance (Trac-B client,
personal communication, September 2017). Many IDUs report living in a low-SES area or are
homeless, therefore it is difficult for them to maintain their hygiene and appearances (Trac-B
client, personal communication, September 2017). Although a prescription is no longer required
to purchase syringes, access to sterile syringes continues to be problematic for IDUs resulting in
the reuse and sharing of injection equipment (Strenski, 2000).
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One of the consequences of sharing syringes is that HIV can survive in a syringe up to 42
days depending on temperature and other factors (CDC, 2018d). One study found that a single
syringe is used an average of 10.7 times by an IDU (Rich, Strong, Towe, & Mckenzie, 1999),
making their risk for HIV/HCV infection considerably high. Studies have shown SEPs may
decrease rates of HIV drug risk behavior and may prevent HIV/HCV transmission (Aldrich,
1993). In addition, SEPs are cost-effective, costing less than $100,000 as compared to the
lifetime cost of treating one HIV-infected individual, which may be as high as $379,668
(Aldrich, 1993; CDC, 2017a).
Nevada & the Opioid Epidemic
Not all states within the U.S. are affected by the opioid epidemic equally. Currently, 2.9
million people reside in the state of Nevada and 75% of Nevada residents (2.5 million people)
live in Clark County (Southern Nevada) (U.S. Census Bureau, 2018a). According to Nevada’s
Prescription Drug Monitoring Program (PDMP), approximately 2.5 million opioid prescriptions
were administered in 2016 (Nevada Division of Public and Behavioral Health, 2017). This is
equivalent to having one opioid prescription for each adult and child who reside in Clark County.
Nevada has one of the highest rates for opioid prescriptions per capita (CDC, 2017b) and
Nevada was one of the top five states for HIV diagnoses rates among adults and adolescents in
2016 (CDC, 2018d). HIV outbreaks are recurring; the most recent HIV outbreak included 11
cases involving injection drug abuse (CDC, 2018d). With the current prescription rate in Nevada
and the number of heroin and injection drug users on the rise, an HIV or HCV outbreak may be
inevitable without intervention.
Trac-B-Exchange
As of February 2017, Trac-B-Exchange (Trac-B) became Clark County’s first SEP. TracB is also the first SEP in the U.S. to distribute syringe kits through vending machines. Trac-B
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distributes sterile needles, injection equipment (i.e. tourniquets, water, cookers, etc.), safe sex
kits, Naloxone kits (overdose reversal drug), and offers various services. These services include
HIV/HCV testing, referrals to treatment facilities, safe injection education, how to administer
Naloxone appropriately, and promote used syringe disposal. There are currently three vending
machine locations in Clark County as well as the storefront location. These vending machines
increase access of sterile equipment, supply a greater number of IDUs, and provide a safe place
to dispose of used syringes. In addition, before the distribution of any equipment or services are
given to an IDU, the completion of specific forms is mandatory. This provides valuable
information about a poorly understood population within Southern Nevada.
Previous Investigations in Nevada
There have been few population-based studies investigating the clinical and sociodemographic data associated to opioid use (Feng et al., 2016; Frank, 2000)”, particularly in
Nevada. One recent Nevada study was conducted by Feng et al. (2016) in Clark County. They
retrieved CHIA data from 2011 to 2013 and analyzed opioid-related injuries under ICD-9-CM
codes. Since October 2015, ICD-10-CM codes have been gradually implemented into healthcare
settings and have increased opioid-related diagnoses from 20 to 100 codes (Moore, 2017). Since
this change, it was reported that opioid-related hospitalizations had increased 18.3% within the
first quarter of ICD-10-CM implementation (Moore, 2017). The modification to ICD-10-CM
codes has increased the number of inpatient (IP) visits and increased the overall cost of opioidrelated hospitalizations, therefore adding to the cost burden of the opioid epidemic. The data
presented on Nevada’s Opioid Dashboard (2016), presents emergency department and IP
admissions only and does not account for those who use illicit opioids. Since the opening of
Clark County’s first SEP, we now have the tools necessary to research a poorly understood
population within Southern Nevada.
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Research Questions
Given the lack of clinical and socio-demographic population-based studies associated
with opioid use in Nevada (Feng et al., 2016; Frank, 2000); this study supplements current
knowledge and provides an updated analysis of opioid-related injuries from a clinical
perspective. In addition, there have been no recent investigations to our knowledge on the sociodemographic subgroups and injection drug practices of IDUs within Clark County; therefore, this
study expands our knowledge on a poorly understood population. The following questions were
investigated: What are the frequent comorbidities and costs associated with opioid-related
inpatient hospital stays in Nevada? What are the socio-demographic subgroups and drug
injection patterns of intravenous drug users within Clark County? Is there a difference in
socioeconomic status (SES) between those who are hospitalized for opioid-related injuries
compared to IDUs who use Trac-B?
Hypotheses
My study provides an updated analysis of opioid-related hospitalizations within the state
of Nevada, and provides a first-time analysis of the IDU population within Clark County using
data from a local SEP. By analyzing 2017 CHIA data, the correlation between the total number
of comorbidities associated with opioid-related injuries and cost was determined. The sociodemographic subgroups for both CHIA and Trac-B data; and the drug injection practices of the
IDU population within Clark County was analyzed. Lastly, the geographical patterns among
those who use hospitals and those who use SEPs was determined.
Objective 1
To determine the frequent comorbidities and cost-associated with IP opioid-related
injuries.
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Objective 2
To determine the socio-demographic subgroups and drug injection practices of the IDU
population within Clark County.
Objective 3
To determine if there is a difference in geographical patterns based on income among
those who use hospitals and those who use SEPs.
Hypotheses
To answer the research question, the following hypotheses will be tested.
Hypothesis 1
Ho: Increasing costs will not be positively associated with the total number of
comorbidities.
Ha: Increasing costs will be positively associated with the total number of comorbidities.
Prediction: The number of comorbidities will be positively correlated with higher costs.
Hypothesis 2
Ho: There will be no difference in socio-demographic subgroups of those who use
hospitals and those who use SEPs.
Ha: There will be a difference in socio-demographic subgroups of those who use hospitals
and those who use SEPs.
Prediction: There will be a difference in socio-demographic subgroups of those who use
hospitals and those who use SEPs.
Hypothesis 3
Ho: There will be no difference in geographical patterns based on income among those
who use hospitals and those who use SEPS.
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Ha: There will be a difference in geographical patterns based on income among those
who use hospitals and those who use SEPs.
Prediction: A higher frequency of IDUs will be seen in zip codes of higher need and a
higher frequency of opioid-related hospitalizations will be seen in zip codes of lower
need.
Methods
This is a cross-sectional, population-based study that used hospitalization data from
CHIA and IDU data from Trac-B. CHIA includes patient billing discharge data from all
hospitals and ambulatory surgical centers licensed to operate in Nevada. ICD-10-CM diagnoses
codes that include any variation of opioid abuse or dependency (see Appendix A for ICD-10-CM
diagnoses codes) were used to measure the frequency of opioid-related hospitalizations from the
CHIA database, identified as having an appropriate ICD-10-CM diagnosis in one of the primary,
secondary, or tertiary diagnosis variables. Client information from Trac-B’s database is selfreported and all registered participants were considered IDUs.
Study Sample
The study sample included 9,064 opioid-related hospitalizations provided by the 2017
CHIA database and 1,252 clients (IDUs) who registered at Trac-B from February 2017 to
February 2018.
Statistical Analysis
All data were analyzed using IBM SPSS Statistics 24.0 software. The first hypothesis
was tested by examining total costs as a function of number of comorbid conditions associated
with opioid-related injuries using a Spearman-rank correlation. In addition, total costs as a
function of length of stay (LOS) of opioid-related hospitalizations was investigated using
Spearman-rank correlation.
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The second hypothesis involved the analysis of frequencies for each demographic
variable of interest in both CHIA and Trac-B datasets using contingency tables and chi-square
statistics. The variables assessed from both CHIA and Trac-B, included age, gender, and
race/ethnicity. In addition, analyses included variables available in Trac-B data only, including
drugs injected, frequency of injection per day, sharing characteristics, and Naloxone distribution.
Finally, for the third hypothesis, a Geographical Information System (GIS; ArcMap
10.3.1, ESRI) map was generated to indicate the SocioNeeds index of each Clark County zip
code. This index is calculated nationwide and ranks each zip code within the U.S. from zero to
100 (Healthy Southern Nevada: SocioNeeds Index, 2018). The SocioNeeds Index (2018) takes
into account SES factors, such as, poverty level and education and then assigns an index number
to the zip code area. An index of 100 indicates areas of high need and correlates with high rates
of preventable hospitalizations and premature death. An index approaching zero, indicates areas
of low need and low rates of preventable hospitalizations and premature death. An index of 50
would indicate the national average. This index was used to determine each SocioNeeds rank of
each zip code within Clark County, as well as, generate maps to indicate the frequency of opioidrelated hospitalizations and injection drug usage within Clark County.
Ethical Considerations
This project has been approved by the UNLV Office of Research Integrity for Exempt
IRB approval for secondary analysis of de-identified data (Appendix C). Additionally, the Data
Use Agreement between CHIA and the School of Community Health Sciences (SCHS) was
approved by the State (Nevada Division of Health Care Financing and Policy).
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Results
According to 2017 CHIA data, there was a total of 9,064 opioid-related inpatient cases.
Of the 9,064 opioid-related cases, 5,268 were Clark County residents. Within Trac-B’s first year
of opening, 1,252 IDUs became registered clients.
Cost Analysis & the Number of Comorbidities
Using 2017 CHIA data, opioid-related hospitalizations were first isolated. Next,
comorbidities associated with opioid-related injuries were grouped by comorbidity category and
ranked by frequency (Table 1).
Table 1. Top 10 Comorbidity Categories Associated with Opioid-Related Hospitalizations
Rank
ICD-10 Codes
Comorbidity Categories

Frequency

1

A00-B99

Certain infectious and parasitic diseases*

41356

2

C00-D49

Neoplasms

15206

3

F01-F99

Mental, Behavioral and Neurodevelopmental disorders*

11802

4

E00-E89

Endocrine, nutritional and metabolic diseases

5761

5

D50-D89

Diseases of the blood and blood-forming organs and certain
disorders involving the immune mechanism

4603

6

I00-I99

Diseases of the circulatory system

2659

7

G00-G99

Diseases of the nervous system

2618

8

S00-T88

Injury, poisoning and certain other consequences of external
causes

1288

9

M00-M99

Diseases of the musculoskeletal system and connective tissue

1129

10

K00-K95

Diseases of the digestive system

1074

*Breakdowns of the comorbidity categories: certain infectious and parasitic diseases; and mental, behavioral and neurodevelopmental disorders are in appendix B.

It was determined the categories of highest frequency of comorbidities associated to opioidrelated hospitalizations included: certain infectious and parasitic diseases; neoplasms; mental,
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behavioral and neurodevelopmental disorders; Endocrine, nutritional and metabolic diseases; and
diseases of the blood and blood-forming organs and certain disorders involving the immune
mechanism.
Cost analysis was conducted by taking “Total Charge” of the comorbidity categories
listed in Table 1 and the “Total Number of Comorbidities.” It should be noted that data are not
cost-equalized among participating hospitals in the data. Spearman-rank correlation suggested
increasing costs was positively associated with the total number of comorbidities listed in Table
1 (Spearman rho value = 0.046, p <0.0001), but the magnitude of the effect was small. This
indicates the correlation between “Total Charge” and the “Total Number of Comorbidities” is
most likely not useful.
Because there were several ICD-10 codes within each comorbidity category, the top 10
specific ICD-10 codes associated with opioid-related injuries were identified and ranked by
frequency (Table 2).

Table 2. Top 10 Comorbidity Specific ICD-10 Codes Associated to Opioid-Related Hospitalizations
Rank

ICD-10 Codes

Comorbidity Specific Category

Frequency

1

G8929/G894/M549

Chronic Bodily Pains

4549

2

E785/E876/E871/E860

Malnutrition

4288

3

F17210/F17200/Z87891

Nicotine Dependence

4050

4

F419/F329

Affective Disorder

2939

5

I10

Hypertension

2607

6

K219

Gastro-Esophageal Reflux Disease

1204

7

N179

Acute Kidney Failure

983

8

J449

Chronic Obstructive Pulmonary Disease (COPD)

901

9

R45851

Suicidal Ideations

900

10

D649

Anemia

772
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The ICD-10 codes of highest frequency for comorbidities associated with opioid-related
hospitalizations included: chronic bodily pains, malnutrition, nicotine dependence, affective
disorder, and hypertension (Table 2). The specific ICD-10 code comorbidity categories in Table
2 were different from Table 1; therefore, a repeated cost analysis was performed for Table 2.
Cost analysis was conducted by taking “Total Charge” and the “Total Number of ICD-10 Codes”
listed in Table 2. Spearman-rank correlation suggested increasing costs was positively associated
with the total number of ICD-10 Codes listed in Table 2 (Spearman rho value = 0.036, p
<0.0001); however, the magnitude of the effect was small. This indicates the correlation between
“Total Charge” and the “Total Number of ICD-10 Codes” may not be useful.
Cost Analysis & the Length of Stay
To further analyze the “Total Charge”, analysis of the “LOS” from the comorbidity
categories listed in Table 1 indicated there was no correlation (Spearman rho = 0.008, p = 0.46);
however, this value was not statistically significant. This process was repeated using the ICD-10
codes listed in Table 2, which showed a positive correlation between “LOS” and “Total Charge”
for specific ICD-10 codes (Spearman rho = 0.378, p < 0.0001). The Spearman rank value
indicates there is a positive correlation between “Total Charge” and “LOS” when analyzing
specific ICD-10 codes (Table 2).
Socio-demographic Subgroups
Age Groups – Cross tabulations among each age group between CHIA hospitalizations
and Trac-B clients indicated there was no significant difference in the proportion of those 17
years or younger (Table 3).
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Table 3. CHIA 2017 IP & Trac-B 2017 IDU Population Demographics*
CHIA
Trac-B
Characteristics
n (%)
n (%)
Age (years)

Test Statistic

Significance

n = 9064

n = 1252

≤ 17

90 (1.0)

16 (1.3)

18-35

2937 (32.4)

586 (46.8)

36-64

4488 (49.5)

446 (35.6)

x2 = 122.3

CHIA > Trac-B

≥ 65

1549 (17.1)

169 (13.5)

p < .001

CHIA > Trac-B

--

35 (2.8)

Female

4575 (50.5)

428 (34.2)

z = 32.7

% Female:

Male

4489 (49.5)

796 (63.6)

p < .001

CHIA>Trac-B

Female to Male

--

1 (0.1)

% Male:

Male to Female

--

2 (0.2)

CHIA < Trac-B

No Response

--

25 (2.0)

White/Caucasian

6670 (73.6)

928 (74.1)

Black/African American

926 (10.2)

22 (1.8)

x2= 238.05

Asian/Pacific Islander

92 (1.0)

13 (1.0)

p < .001

Native American/Alaskan

108 (1.2)

30 (2.4)

Other

496 (5.5)

186 (14.8)

--

73 (5.9)

Unknown

246 (2.7)

--

Hispanic

526 (5.8)

--

No Response

CHIA < Trac-B

Gender

Race/Ethnicity

No Response

Hispanic/Latino
Yes

192 (15.3)

No

908 (72.5)

No Response

152 (12.2)

*Trac-B data includes data from February 2017 through February 2018.

There was a significant difference between CHIA and Trac-B samples among all other age
groups (x2 = 122.33, p < 0.001). There was a higher proportion of those in the age group 18-35
13

years, who used SEPs as compared to the 18-35 year olds who used hospitals (Table 3). There
was a higher proportion of those who were 36 years old or older, who used hospitals as
compared to those in the same age group who used SEPs (Table 3).
Gender – There appears to be an association between those who use hospitals versus
SEPs and gender (z = 32.7, p < 0.001) (Table 3). There were significantly more females who
used hospitals as opposed to females who used SEPs. On the contrary, there were significantly
more males who used SEPs as opposed to males who used hospitals.
Race & Ethnicity – There was a significant difference in the proportion of those who are
of Black/African American race/ethnicity, who used hospitals as compared to the Black/African
Americans who used SEPs (Table 3). There was a significant difference in the proportion of
those who are of Native American/Alaskan race/ethnicity, who used SEPs as compared to Native
American/Alaskans who used hospitals (Table 3). In addition, the proportion of those who are of
Other race/ethnicity was significantly different from those who used SEPs as compared to Other
race/ethnicity who used hospitals (Table 3). There were no significant differences between the
White/Caucasian race/ethnicity groups among CHIA and Trac-B data.
Trac-B Injection Demographics
There was a high percentage of IDUs who reported injecting heroin, followed by
methamphetamines, and speedball (Table 4).
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Table 4. First Year Trac-B-Exchange Drug Preference of IDU Population
Yes
Drugs Used*
n (%)

No
n (%)

Heroin

889 (71.0)

363 (29.0)

Methamphetamines

767 (61.3)

485 (38.7)

Speedball1

342 (27.3)

910 (72.7)

Cocaine

139 (11.1)

1113 (88.9)

Opioids

179 (14.3)

1073 (85.7)

Steroids1

45 (3.6)

1207 (96.4)

Hormones1

19 (1.5)

1233 (98.5)

*Data does not reflect if the Trac-B client marked multiple drugs on one survey.
1. Speedball is a mixture of heroin and cocaine, steroids and hormones may be injected illegally by the transgender population

The majority of IDUs reported injecting four to 10 times per day, followed by
0-3 times per day, and a low rate of IDUs reported injecting greater than 10 times per day (Table
5).

Table 5. First Year Trac-B-Exchange Injection Patterns of IDU Population
Injection Times per Day

n (%) = 1252 (100)

0 – 3 times

463 (37.0)

4 to 10 times

540 (43.1)

>10 times

51 (4.1)

Rarely1

57 (4.6)

Other Response*

10 (0.8)

No Response

131 (10.5)

*Other Response = answers that were difficult to place in an Injection category.
1.Rarely = may inject 5 times per week or month

Of the IDUs who participated in Trac-B’s program, many reported to have shared drugs, have
shared injection equipment, and have shared needles (Table 6).
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Table 6. First Year Trac-B-Exchange Sharing Characteristics of IDU Population
Sharing Characteristics
Yes
I have in the past
n = 1252
n (%)
n (%)

No
n (%)

No Response
n (%)

Share Drugs

671 (53.6)

--

540 (43.1)

41 (3.3)

Sharing Equipment

332 (26.4)

--

853 (68.1)

67 (5.4)

Sharing Needles

162 (12.9)

4 (0.4)

1038 (82.9)

48 (3.8)

Trac-B data indicated 421 Narcan/Naloxone kits were distributed; however, this includes
initial kits and refills. The data reflects clients who may have received multiple kits within the
past year. Most of the Narcan/Naloxone kits were given to those who were between the ages of
18 to 34 years (Table 7).
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Table 7. Trac-B-Exchange Naloxone Kit Distribution by Age & Gender of IDU Population
Characteristic

Mean
Age

Median
Age

Mode
Age

(Min, Max)
Age

n (%)

Age (years)

34.93

33.00

27.00

(11, 67)

n=421 (100)

≤ 17

1 (0.2)

18-34

229 (54.4)

35-52

135 (32.1)

53-71

40 (9.5)

72-88

0 (0.0)

No Response

16 (3.8)

Gender
Female

136 (32.3)

Male

194 (46.1)

Female to Male

0 (0.0)

Male to Female

2 (0.5)

Other

1 (0.2)

No Response

88 (20.9)

Males were more likely to request Narcan/Naloxone kits compared to other gender groups.
Geographical Patterns Based on Income
The SocioNeeds Index ranks each zip code within the U.S. from 0-100; however, for this
study it was modified to five ranks for simplicity (1 = area of low need, 5 = area of high need)
(Figure 1).
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Figure 1. Clark County zip codes by SocioNeeds Index

Many zip codes within the center of Clark County (red regions) are areas of high need, which
indicates a high rate of poor health outcomes. As the map branches out from the center of Clark
County, more urban areas are designated by the color green, indicating areas of low need or low
rates of poor health outcomes (Figure 1).
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Homelessness
The SocioNeeds Index does not include those who may be transient or of homeless
status. CHIA data do not provide this information directly; however, CHIA data do provide a
code, Payer 23, which indicates County Indigent Referral. Those who claim Payer 23 are unable
to pay for their hospital care and may have alternative ways to pay for their medical expenses or
they may be transient. In 2017, 169 (1.86%) opioid-related cases reported Payer 23, which likely
captures the transient population in the database.
Trac-B’s data directly provides homelessness status because of the required registration
forms that are mandatory before equipment are dispersed. Based on self-reported data, 378
(30.2%) of Trac-B’s clientele reported homelessness status.
Cases by Zip Code
Using Clark County zip code maps, frequencies of CHIA opioid-related cases were colorcoded within each zip code (Figure 2).
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Figure 2. Clark County Frequency of Opioid-Related Cases by Zip Code.

The zip codes that are red, indicate where opioid-related injuries were highest for 2017.
The red area near the letter A, is zip code 89108, which is known for section 8 housing and
borders an area known for high crime. The red areas near letters B and C, indicate zip codes
close to medical facilities (B – Spring Valley Hospital; C – UMC Hospital). The majority of the
red areas on Figure 2, associate with a high SocioNeeds index.
Trac-B clientele revealed only two zip codes with a high frequency of injection drug use
(Figure 3).
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Figure 3. Clark County Frequency of Intravenous Drug Users by Zip Code

The red area near A (Figure 3) is zip code 89108 and is a common zip code for a high
frequency of opioid-related hospitalizations seen in Figure 2. The red area near D (Figure 3) is
the zip code 89107 and borders the street that Trac-B’s storefront is located. Because 30.2% of
Trac-B’s clientele reported homelessness, we can expect the majority of clients to travel by foot
or bike because of their close residence to Trac-B. There were no other shared zip codes in terms
of high frequencies for hospitalizations and injection drug use.
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There were six total zip codes within Clark County to have a high frequency of opioidrelated hospitalizations and two zip codes within Clark County to have a high frequency of
injection drug use. The zip code 89108, demonstrated both a high frequency of opioid-related
hospitalizations and injection drug use; in addition, it is an area of high need according to the
SocioNeeds Index (Figure 1).
Discussion
In 2017, there were 9,064 opioid-related hospitalizations (ORH) in Nevada State, of these
5,268 occurred within Clark County. This is an increase compared to Feng et al.’s (2016) Clark
County study, where they found 5,016 ORHs within a 3-year time frame from 2011-2013. This
increase in ORHs could be the result of Nevada’s high prescription rate, contributing to the
opioid epidemic, or a result of differences in codes used for data extraction under ICD-10 as
discussed below.
This study revealed that 58% (n=5,268) of ORH’s occurred in Clark County in 2017,
which is surprisingly low considering 75% of Nevada residents live in Clark County (U.S.
Census Bureau, 2018a). The remainder 42% of ORHs that occurred in 2017 happened in less
populated areas of Nevada. Aside from Clark County (population = 2.2 million) (U.S. Census
Bureau, 2018b) and Washoe County (population = 460,587) (U.S. Census Bureau, 2018c), all
other counties within Nevada do not exceed a population of 54,745 residents, with Esmeralda
County having the lowest population of 850 residents (U.S. Census Bureau, 2018d). This may be
evidence that many of the ORHs could be occurring in more rural areas of Nevada or medical
facilities within these areas are capturing more ORHs.
Comorbidities Associated to Opioid-Related Hospitalizations
When investigating comorbidities associated with ORHs, many of the comorbidities with
high frequencies were consistent with Feng et al.’s (2016) study; such as: chronic bodily pains,
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affective disorders, hypertension, renal failure, and chronic lower respiratory disease. When
looking at the number of cases for chronic bodily pains, Feng et al. (2016) found 2,253 cases
between 2011 and 2013; however, for 2017 there were 4,549 ORHs associated with chronic
bodily pains. According to the Nevada Division of Public and Behavioral Health (2017), opioidrelated hospitalizations have increased substantially since 2011 in both emergency department
(ED) visits and hospitalizations; however, there may be another explanation that may account for
this increase.
Moore and Barrett (2017) found within the first quarter of ICD-10-CM implementation,
ORIs increased by 18.3%. Previously, under the ICD-9-CM coding system there were 20 opioidrelated codes; however, under the ICD-10-CM coding system ORI’s became more specified,
increasing from 20 to 100 opioid-related codes. This modification allowed medical facilities to
accurately diagnose ORI’s compared to previous years using ICD-9-CM codes. Feng et al.’s
(2016) study investigated CHIA data from 2011 to 2013; however, ICD-10-CM implementation
began October 2015. It is possible that ORIs may not have been accurately diagnosed leading to
a misrepresentation of the number of ORIs within the timeframe of their study. This project
analyzed CHIA data from 2017 that implemented ICD-10-CM codes providing an updated
analysis of ORHs within Nevada and Clark County. Having an accurate analysis of ORHs will
allow Nevada public health officials to observe trends of opioid abuse and will aid in appropriate
opioid-related interventions.
Cost Analysis
When analyzing the number of comorbidities and cost, unexpectedly there were no
meaningful correlations observed. It is possible a single comorbidity may have a higher cost
compared to a patient who had three comorbidities of lower value; alternatively, after examining
LOS associated with cost, a potential story emerged. Using the ICD-10-CM codes listed in Table
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2, a positive correlation between LOS and cost was observed; therefore, longer hospital stays
accrue higher costs.
In addition, the mean cost evaluated for ORHs for 2017 (n=9,064) was estimated to be
$72,632 with the mean LOS of approximately 7 days. Looking at all hospitalizations for 2017
(n=352,262), the mean cost was $74,975 with the mean LOS of 5.27 days. When comparing
ORHs to all hospitalizations for 2017, the LOS was higher for ORHs. Considering that LOS is
positively associated with higher cost, we can expect those hospitalized for an ORI may be
accruing higher hospital costs as a function of longer stays. On the contrary, the mean cost was
estimated to be lower for ORHs when compared to all hospitalizations; however, it was not
meaningfully different from the mean cost of all hospitalizations. Further, costs are not
universally standardized across procedures at different hospitals, which could confound the
comparisons.
Trac-B Analysis
Analysis of Trac-B’s first year of clientele, revealed that 71% of IDUs inject heroin and
the average IDU injects 4-10 times per day. In addition, sharing characteristics revealed IDUs are
sharing equipment and syringes; however, there was a higher percentage of those that reported
sharing drugs. The question of whether an IDU shares drugs may have several interpretations.
For instance, are IDUs simply giving a dose to their friend before it is cooked? Or are two IDUs
putting both of their syringes into the same cooker and taking in their dose? Because 53.6%
reported sharing drugs, it is possible that they are also sharing equipment, resulting in the
potential for infectious disease transmission. Because these questions are based on self-reported
surveys, the interpretation of this question by IDUs may be unclear; therefore, revealing areas of
improvement within Trac-B’s surveys. In addition, this analysis provides valuable information
for the purposes of research and the services offered in their facility.
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For 2017, Trac-B had successfully distributed 206,140 sterile syringes; disposed of
105,136 used syringes; and administered 130 HIV and 101 HCV tests. Of these tests, three
(2.3%) positive HIV and 32 (31.7%) positive HCV tests were confirmed. Clients who tested
positive were contacted by a representative from the Southern Nevada Health District and
referred for treatment. The current AIDS foundation in Clark County, Aid for AIDS of Nevada
(AFAN) reported administering 100 HIV tests for the year 2017 and found that two of these tests
were positive (AFAN representative, personal communication, October 2018). AFAN is not
specific about who they test; however, Trac-B’s target population is of a high-risk group known
for high rates of HIV/HCV transmission. This emphasizes the importance of Trac-B’s services
within the community.
Of the 206,000 sterile syringes distributed, 14,000 were dispersed through Trac-B’s
vending machines. The average cost of a single syringe is approximately $0.08 and each syringe
is equivalent to one prevented HIV infected person, which may cost up to $379,668 for a single
lifetime of HIV treatment (Aldrich, 1993; CDC, 2017a). Trac-B’s innovative method of
distributing syringe kits through vending machines is not only cost-effective, but allows more
IDUs to access sterile injection equipment. By identifying zip codes with high frequencies for
both ORHs and IDUs, Trac-B can strategically place future vending machines in these locations,
increasing access to sterile injection equipment; therefore, preventing the transmission of
HIV/HCV. In addition, Trac-B offers an array of services to IDUs, proving to be a public health
asset to the state of Nevada by filling in the gap between a high-risk population in need and
access to health care.
Currently, Trac-B is grant funded and most SEPs in the U.S. are not federally funded
(Jarlais, McKnight, & Milliken, 2004). Many are funded through foundation grants and/or
private donations (Jarlais, McKnight, & Milliken, 2004). SEPs are experiencing a financial crisis
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due to the ban on federal funding, in addition HIV prevention funds have been reallocated away
from IDU transmission (Guardino, Des Jarlais, Nugent & Purchase, 2014). This federal ban was
one of the contributing factors for the 2015 HIV outbreak that occurred in Scott County, Indiana
(Rich & Adashi, 2015). There were approximately 153 confirmed HIV cases that were the result
of syringe sharing in this low-income community (Rich & Adashi, 2015). Many researchers
suggest this preventable incident will happen again, as long as SEPs remain illegal in many states
(Rich & Adashi, 2015). In fact, SEPs have been controversial since the wake of their
development during the HIV pandemic in the 1980’s.
The controversy behind the legalization of SEPs was argued by many public officials
believing SEPs would promote and exacerbate the injection of drugs, as well as increase the
incidence of HIV cases (Rich & Adashi, 2015). However, decades of research investigations
demonstrate that SEPs are safe and effective at reducing disease transmission and promoting
referral to treatment facilities (Rich & Adashi, 2015). One study found that SEPs had increased
in quantity from 60 SEPs within the U.S. in 1994 to approximately 127 in 2000 (Jarlais,
McKnight, & Milliken, 2004), indicating the increased acceptance of SEPs within communities
and the role they play in HIV prevention. However, as previously mentioned many states refuse
to legalize SEPs, despite decades of research demonstrating SEP effectiveness.
The cost-efficiency of SEPs (less than $100,000 annually) versus the overall opioid
epidemic cost burden of 504 billion dollars is incomparable (HHS, 2017b). The first-year
analysis of Trac-B’s data has proven to be an effective intervention on combating the public
health concerns resulting from the current opioid epidemic. Given the information derived from
this study, it is evident that SEPs provide one potential solution or a gateway to addressing many
public health concerns resulting from the opioid epidemic.
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Socio-Demographic Subgroups
Analysis of the socio-demographic subgroups demonstrated that a higher proportion of
18-35 year olds used SEPs as compared to 18-35 year olds who were admitted into hospitals for
ORIs. In addition, there was a higher proportion of males registered as clients at Trac-B as
opposed to the proportion of males who were hospitalized for ORIs. This is consistent with the
literature showing that most IDUs are men of younger age groups (Cicero et al., 2014). On the
other hand, there was a higher proportion of those 36 years of age or older who were admitted
for ORH compared to those in the same age group who used Trac-B’s services, a similarity seen
in Feng et al.’s (2016) study. By having a younger age group use Trac-B for its services, there
may be an associated reduction in future hospitalizations when these 18-35 year olds reach the
older age groups of 36 years and above.
In addition, there was a higher proportion of females who were admitted in 2017 for
ORIs compared to females who registered as clients at Trac-B providing a consistent trend of
what was seen in Feng et al.’s (2016) study. A higher proportion of ORHs were among females,
aged 55 years and older. These results demonstrate that gender specific interventions are
necessary to battle prescription opioid abuse as well as injection drug abuse.
SocioNeeds Index
Density maps identified zip code 89108 as having high rates for both ORHs and IDUs for
2017. In addition, the SocioNeeds index map determined that 89108 is an area of high need or
low-SES. This implies zip code 89108 as being an area of high priority for intervention regarding
the adverse outcomes of the opioid epidemic. All factors associated to low-SES may be
contributing factors to the high rates of ORHs and intravenous drug use. Currently, 89108 has a
population of 76,236 residents (Healthy Southern Nevada, 2018), is known to have section-eight
housing, and borders a North Las Vegas community known for high crime rates. In 2017, 247
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ORHs and 96 IDUs reported this area as their zip code of residence. It is evident that
interventions need to be targeted in this area, specifically addressing the contributing factors of
prescription opioid abuse and the injection of illicit opioids in low-SES communities.
CHIA zip code areas
Five out of the six zip codes that demonstrated a high frequency for ORHs were areas
with a high SocioNeeds Index. The sixth zip code (Figure 2 – red area above the letter B) had a
SocioNeeds Index that was average to the nation – meaning it’s a typical middle class
community that demonstrated high rates for ORHs. When combating the effects of the opioid
epidemic, interventions may not be a one-size fits all solution. Interventions among different
SocioNeeds Index communities may require tailored programs to address the specific needs of
the population. In addition, studies identifying what is driving ORHs in this middle-class
community as opposed to the higher need areas is suggested.
Trac-B zip code areas
There were only two zip codes within Clark County to demonstrate high frequencies for
IDUs: 89108 (previously discussed) and 89107. The zip code 89107 (population = 37,908) is
located directly below 89108, is an area of high need, and borders the street where Trac-B’s
storefront is located. Considering 30.2% of Trac-B’s clientele reported homelessness, this could
explain the close-proximity of IDUs in 89108 and 89107. We would expect many of these clients
to be walking, riding their bikes, or using another form of transportation associated to closeproximity to Trac-B. This is an important factor to consider when determining the location of a
potential SEP storefront location or when distributing new vending machines.
National Policy on Prescription Opioids
Currently, the regulation of prescription opioids is the responsibility of the states,
meaning there are no national laws in the regulation of prescription opioids (CDC, 2018e).
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However, a CDC funded program called ‘Prevention for States’ was designed to provide state
funding to battle the ongoing prescription drug overdose epidemic (CDC, 2017c). There are
currently 29 states receiving CDC funds within the program including Nevada. The strategies of
‘Prevention for States’ include: maximizing Prescription Drug Monitoring Programs (PDMP),
community or insurer/health systems interventions, policy evaluations, and rapid response
projects (CDC, 2017c).
‘Prevention for States’ is fairly new and not all states are funded. Because there is little
research on the effectiveness of state regulations regarding the abuse of prescription drugs (CDC,
2018f), this program may provide the necessary data to determine the impact it has on
prescription drugs and overdose. In addition, because the regulation of prescription opioids are
within the responsibility of the states, some states have implemented state-level policies that
regulate pain clinics and PDMPs, successfully reducing their overdose rate.
States such as, Florida, New York, Tennessee, Ohio, and Kentucky (CDC, 2017d) have
established PDMPs, mandating that all providers check the PDMP before prescribing opioids.
Many of these states have shown reductions in the number of patients seeking multiple providers
for the same drugs within two years of PDMP establishment. Florida had implemented several
interventions targeting excessive opioid prescribing from pain clinics in addition to mandating
PDMPs, resulting in an 80% opioid prescription decrease from 2010 to 2015 (CDC, 2017d).
Within the five-year timeframe, Florida simultaneously saw a reduction in prescription opioid
overdose rates (CDC, 2017d). In 2012, Florida specifically saw greater than 50% of oxycodone
overdose deaths decrease, which was a direct effect of preventing health care providers from
dispensing prescription opioids from their offices and having an established PDMP (CDC,
2017d). According to the CDC (2017d), this is the first substantial decrease in drug overdose
mortality in the past 10 years (CDC, 2017d).
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Nevada Policy on Prescription Opioids
As of January 1, 2018, Nevada implemented the Nevada Prescription Drug Abuse
Prevention Act (Assembly Bill 474 or AB 474) to curb opioid abuse within the State
(Gov.nv.gov, 2017). AB 474 mandates additional requirements before administering controlled
substance prescriptions with the purpose of reducing inappropriate prescribing, and hence,
preventing addiction (Gov.nv.gov, 2017). Although it does not prevent health care providers
from dispensing prescription opioids from their offices like Florida, it may encourage clinicians
to find an alternative form of treatment for patients. It will be interesting to see if and how the
trends of ORHs have changed during 2018 and within the next five years. If this new policy
decreases the opioid prescriptions per capita in Nevada, but ORHs continue to increase, this may
suggest the increased abuse of illicit opioids sold on the black market. In addition, continued
analysis of Trac-B’s data may also contribute valuable information of changing trends of ORHs.
This epidemic has led to a chain reaction of public health concerns: addiction, heroin
usage, injection drug abuse, and HIV/HCV transmission. With Nevada having one of the highest
rates for opioid prescriptions per capita, it is imperative to understand trends of opioid-related
hospitalizations and intravenous drug use. Only then can we implement interventions and
programs to battle the opioid epidemic and the consequent public health effects.
Limitations
All research must be presented with appropriate caveats, and the limitations of this
research are highlighted here. CHIA data were de-identified, and therefore, repeat IP admissions
may have occurred. Trac-B clientele are not required to show identification upon registration. All
data received from Trac-B are self-reported, which is susceptible to misclassification bias.
Respondents may over- or under-report drugs they have used or how many times they inject per
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day. In addition, the survey data may not reflect true birth dates, gender, race/ethnicity, or zip
code.
The cost analyzed in this project was not weighted by medical facility procedural
multipliers; therefore, the total charges assessed may not be comparable. In addition, the
population within each zip code was not adjusted, but presented in counts. This may influence
the number of ORHs and/or IDUs. A large percentage (30.2%) of IDUs reported homelessness,
which may skew the zip code data if populations were adjusted. However, less than 1.86% of
ORHs claimed Payer 23, which may not influence the zip code data if adjustments were
implemented.
Trac-B services did not start until February 2017, and hence data analyzed included one
month in 2018; CHIA data analyzed included only 2017 data. Trac-B did not start distributing
Naloxone kits until April 2017, and therefore this does not provide a complete year of information
for Naloxone distribution. Clients who seek vending machine access cards may have more than
one access card. They may have changed their name and/or birth date to receive another access
card at a different location, therefore they will be counted as two different clients.
Conclusion
This project provides the most recent analysis of data on Nevada’s opioid-related
hospitalizations, as well as, a first-time analysis of Clark County’s IDU population. This analysis
supplements current research and may serve as a baseline for future research to be done. Only a
few states have implemented prescribing interventions that have demonstrated a decline in the
number of patients seeking multiple providers for the same drugs. Florida is the only state to
have demonstrated substantial reductions in prescription opioid overdose rates. Considering each
state may have demographic differences of those who abuse prescription and illicit opioids, it
will be interesting to see if AB 474 influences ORHs and IDUs in Nevada. This project provides
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information to support harm reduction programs like Trac-B and will hopefully open funding
opportunities for Trac-B to continue their services within Clark County.
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Appendix A
ICD-10 CM Codes for Opioid Related Disorders
1. ICD-10-CM Codes
2. F01-F99 Mental, Behavioral and Neurodevelopmental disorders
3. F10-F19 Mental and behavioral disorders due to psychoactive substance use
Opioid related disorders F11
Clinical Information
•

Disorders related to resulting from abuse or mis-use of opioids.

Codes
F11

Opioid related disorders

F11.1

Opioid abuse

F11.10

uncomplicated

F11.11

in remission

F11.12

Opioid abuse with intoxication

F11.120

uncomplicated

F11.121

delirium

F11.122

with perceptual disturbance

F11.129

unspecified

F11.14

with opioid-induced mood disorder

F11.15

Opioid abuse with opioid-induced psychotic disorder

F11.150

with delusions

F11.151

with hallucinations

F11.159

unspecified

F11.18

Opioid abuse with other opioid-induced disorder

F11.181

Opioid abuse with opioid-induced sexual dysfunction
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F11.182

Opioid abuse with opioid-induced sleep disorder

F11.188

Opioid abuse with other opioid-induced disorder

F11.19

with unspecified opioid-induced disorder

F11.2

Opioid dependence

F11.20

uncomplicated

F11.21

in remission

F11.22

Opioid dependence with intoxication

F11.220

uncomplicated

F11.221

delirium

F11.222

with perceptual disturbance

F11.229

unspecified

F11.23

with withdrawal

F11.24

with opioid-induced mood disorder

F11.25

Opioid dependence with opioid-induced psychotic disorder

F11.250

with delusions

F11.251

with hallucinations

F11.259

unspecified

F11.28

Opioid dependence with other opioid-induced disorder

F11.281

Opioid dependence with opioid-induced sexual dysfunction

F11.282

Opioid dependence with opioid-induced sleep disorder

F11.288

Opioid dependence with other opioid-induced disorder

F11.29

with unspecified opioid-induced disorder

F11.9

Opioid use, unspecified

F11.90

uncomplicated

F11.92

Opioid use, unspecified with intoxication

F11.920

uncomplicated

F11.921

delirium

F11.922

with perceptual disturbance
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F11.929

unspecified

F11.93

with withdrawal

F11.94

with opioid-induced mood disorder

F11.95

Opioid use, unspecified with opioid-induced psychotic disorder

F11.950

with delusions

F11.951

with hallucinations

F11.959

unspecified

F11.98

Opioid use, unspecified with other specified opioid-induced disorder

F11.981

Opioid use, unspecified with opioid-induced sexual dysfunction

F11.982

Opioid use, unspecified with opioid-induced sleep disorder

F11.988

Opioid use, unspecified with other opioid-induced disorder

F11.99

with unspecified opioid-induced disorder
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Appendix B
Specified Diagnoses for Selected Comorbidity Categories
Table 8. Specified Diagnoses of Certain Infectious & Parasitic Diseases
Certain infectious and parasitic diseases A00-B99

Frequency

Bacterial Diseases

10880

Intestinal infectious diseases

7190

Mycoses

4814

STI's

4807

Viral infections characterized by skin and mucous membrane
lesions

3500

Bacterial and viral infectious agents

3247

Viral hepatitis

1931

Other Spirochetal Diseases

1486

Pediculosis, acariasis and other infestations

971

Other viral diseases

910

Tuberculosis

499

Arthropod-Borne Viral Fevers and Viral Hemorrhagic Fevers

286

Other infectious diseases

278

HIV

232

Protozoal diseases

167

Sequelae of infectious and parasitic diseases

158

Total

41356
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Table 9. Specified Diagnoses of Mental, Behavioral and Neurodevelopmental disorders
Mental, Behavioral and Neurodevelopmental disorders F01-F99

Frequency

Mental and behavioral disorders due to psychoactive substance use

n = 3107

Opioid related disorders

646

Alcohol related disorders

522

Other stimulant related disorders

438

Sedative, hypnotic, or anxiolytic related disorders

340

Cannabis related disorders

290

Other psychoactive substance related disorders

289

Cocaine related disorders

270

Nicotine dependence

153

Hallucinogen related disorders

125

Inhalant related disorders

34

Total

3107*

Mood [affective] disorders

658

Anxiety, dissociative, stress-related, somatoform and other
nonpsychotic mental disorders

487

Mental disorders due to known physiological conditions

356

Behavioral syndromes associated with physiological disturbances
and physical factors

224

Disorders of adult personality and behavior

210

Behavioral and emotional disorders with onset usually occurring in
childhood and adolescence
Schizophrenia, schizotypal, delusional, and other non-mood
psychotic disorders

208
198

Pervasive and specific developmental disorders

112

Intellectual disabilities

28

Total

5588

*The total 3107 mental and behavioral disorders due to psychoactive substance use is included in the total 5588 mental, behavioral
and neurodevelopmental disorders.
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Appendix C
Internal Review Board Exclusion
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